Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
Alimentary Pharmacology & Therapeutics · 2023-02 · 57 (4) · 426-434
DOI: 10.1111/apt.17358 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 19.12.2022. Verfasst von Mathurin Fumery und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Amiens University Hospital, and PeriTox, Université de Picardie, Amiens, France. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Phase III trials have demonstrated the efficacy of risankizumab in moderate‐to‐severe Crohn's disease (CD), but no real‐world data are currently available. We aimed to assess the short‐term effectiveness and safety of risankizumab in patients with CD.
Methods
From May 2021 to May 2022, all patients with refractory luminal CD treated with risankizumab in 22 French GETAID centres were retrospectively included. The primary endpoint was steroid‐free clinical remission at week 12 (Harvey‐Bradshaw [HB] score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Amiens University Hospital, and PeriTox, Université de Picardie, Amiens, France.
- Groupe d'étude des Affections Inflammatoires du tube Digestif, GETAID, Paris, France.
- Department of Gastroenterology, CHU of Saint-Etienne, Saint-Etienne, France.
- Department of Gastroenterology, CHU of Montpellier, Montpellier, France.
- Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France.
- Department of Gastroenterology and Clinical Nutrition, CHU of Nice and University Côte d'Azur, Nice, France.
ORCID-Profile: Mathurin Fumery, Xavier Roblin, Romain Altwegg, Antoine Meyer, David Laharie, Mathieu Uzzan, My-Linh Tran-Minh, Lucine Vuitton, Laurent Peyrin-Biroulet
Zitieren
APA
Fumery, M., Defrance, A., Roblin, X., Altwegg, R., Caron, B., Hébuterne, X., Stefanescu, C., Meyer, A., Nachury, M., Laharie, D., Nancey, S., Le Berre, C., Serrero, M., Geyl, S., Giletta, C., Ah-Soune, P., Duveau, N., Uzzan, M., Abitbol, V., …, & Peyrin-Biroulet, L. (2023). Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary Pharmacology & Therapeutics, 57(4), 426-434. https://doi.org/10.1111/apt.17358
Vancouver
Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study. Alimentary Pharmacology & Therapeutics. 2023;57(4):426-434. doi:10.1111/apt.17358
BibTeX
@article{Fumery2023,
author = {Fumery, Mathurin and Defrance, Antoine and Roblin, Xavier and Altwegg, Romain and Caron, Benedicte and Hébuterne, Xavier and Stefanescu, Carmen and Meyer, Antoine and Nachury, Maria and Laharie, David and Nancey, Stephane and Le Berre, Catherine and Serrero, Melanie and Geyl, Sophie and Giletta, Cyrielle and Ah-Soune, Philippe and Duveau, Nicolas and Uzzan, Mathieu and Abitbol, Vered and Biron, Amelie and Tran-Minh, My-Linh and Paupard, Thierry and Vuitton, Lucine and Elgharabawy, Yasmine and Peyrin-Biroulet, Laurent},
title = {Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {4},
pages = {426--434},
doi = {10.1111/apt.17358}
}
EUVIMED